Sequential oncological therapy and delays in oncological diagnostics and treatment
Journal Title: OncoReview - Year 2014, Vol 4, Issue 2
Abstract
One of the causes behind the low recovery rate among oncological patients is late diagnosis and delayed treatment. To a large extent it stems from the limited access to standard diagnostic methods, and from the extended waiting time for medical treatment. Delayed diagnosis or commencement of therapy might be patient-related, doctor-related, or might have more to do with the organization of the healthcare system. It would appear that the greatest problem in Poland is the system-related delay. Studies have demonstrated that delayed treatment might have a significant impact on patient survival. Poor health education of the society, lack of comprehensive treatment, and queues for medical care that patients come across virtually at all treatment stages result in neoplastic diseases being diagnosed in their advanced stage only, with delayed treatment lowering the patients’ chances of complete recovery.
Authors and Affiliations
Karolina Skóra
Keywords
Related Articles
- EP ID EP67757
- DOI -
- Views 206
- Downloads 0
Leczenie chorych na szpiczaka mnogiego poniżej 65.–70. roku życia oraz rola terapii podtrzymującej po przeszczepieniu komórek macierzystych
Leczenie chorych na szpiczaka mnogiego uległo w ostatnim dziesięcioleciu istotnym zmianom, które są wynikiem lepszego zrozumienia biologii schorzenia, zastosowania skuteczniejszych leków i lepszej opieki wspomagającej. W...
Acquired haemophilia in a patient with neoplastic disease
Acquired haemophilia A (AH) is a rare autoimmune disorder caused by inhibitory antibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous personal or family histor...
Invasive fungal infection in a child with Ewing’s sarcoma
Invasive fungal infection (IFI) in patients with malignant solid tumours is rare, but it highly increases the risk of cancer recurrence because of prolonged discontinuation of cancer treatment. This paper presents a case...
Novel oral anticoagulants in the treatment of cancer patients
Cancer and its treatment are well-recognized risk factors for venous thromboembolism. The risk of thrombotic complications increases 4–7-fold in cancer patients and coexistence of both pathologies is associated with shor...
Znaczenie badań molekularnych w kwalifikacji do terapii I linii erlotynibem chorych na NDRP na podstawie wyników badania EURTAC
W latach 2010–2011 pierwszy inhibitor kinazy tyrozynowej EGFR (IKT EGFR) – gefitynib uzyskał w wielu krajach rejestrację do leczenia w I linii chorych na zaawansowanego i miejscowo zaawansowanego niedrobnokomórkowego rak...